Scientific work

Doç. Dr. İzzet Doğan

107 publications. The source of the information is stated next to each publication.

Back to profile

  1. The frequency and prognostic significance of ABO/Rh blood groups in male breast cancer patients: A multicenter study

    Medicine, 2022

    DOI 10.1097/md.0000000000030147 PMID 36107512 3 citations (Europe PMC) Open-access full textSource: OpenAlex

  2. The effectiveness and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early-stage human epidermal growth factor receptor 2-positive breast cancer: Turkish Oncology Group study

    Anti-Cancer Drugs, 2022

    DOI 10.1097/cad.0000000000001310 PMID 35703239 3 citations (Europe PMC) Source: OpenAlex

  3. FOLFIRINOX versus gemcitabine plus nab-paclitaxel as the first-line chemotherapy in metastatic pancreatic cancer

    Journal of Chemotherapy, 2022

    DOI 10.1080/1120009x.2022.2026125 PMID 35037592 15 citations (Europe PMC) Source: OpenAlex

  4. Toxicity management and efficacy of carboplatin desensitization therapy for recurrent epithelial ovarian carcinoma: A real-world study

    Medicine, 2022

    DOI 10.1097/md.0000000000031726 PMID 36397338 4 citations (Europe PMC) Open-access full textSource: OpenAlex

  5. Clinicopathological Features and Prognostic Factors in Patients with Small Bowel Adenocarcinoma

    Bagcilar Medical Bulletin, 2022

    DOI 10.4274/bmb.galenos.2022.2022-02-015 Source: OpenAlex

  6. Hormonal Therapy in Pretreated Patients With Recurrent Ovary Granulosa Cell Tumor

    Journal of Pharmacy Practice, 2022

    DOI 10.1177/08971900221129679 PMID 36148892 2 citations (Europe PMC) Source: OpenAlex

  7. Comparison of Clinical, Pathological, and Prognostic Features in BRCA Mutant and Wild-Type Male Breast Cancer Patients

    European Journal of Breast Health, 2022

    DOI 10.4274/ejbh.galenos.2022.2022-5-2 PMID 36248747 1 citation (Europe PMC) Open-access full textSource: OpenAlex

  8. Efficacy of the VIT (vincristine, irinotecan and temozolomide) regimen in adults with metastatic Ewing sarcoma

    Journal of Chemotherapy, 2022

    DOI 10.1080/1120009x.2022.2104295 PMID 35894948 3 citations (Europe PMC) Source: OpenAlex

  9. Capecitabine and temozolomide ( CAPTEM ) is effective in metastatic well‐differentiated gastrointestinal neuroendocrine tumors

    Journal of Digestive Diseases, 2022

    DOI 10.1111/1751-2980.13123 PMID 36081250 5 citations (Europe PMC) Source: OpenAlex

  10. Crizotinib in Metastatic ALK mutant Non-small Cell Lung Cancer Patients: A Single Centre Experience

    Clinical Cancer Investigation Journal, 2022

    DOI 10.51847/87n2fddtb1 2 citations (OpenAlex) Open-access full textSource: OpenAlex

  11. Clinicopathological Factors in Relation to HER2 Status in Metastatic Gastric Cancer: A Retrospective Observational Study

    Journal of Oncological Sciences, 2022

    DOI 10.37047/jos.2021-86554 Source: OpenAlex

  12. Outcomes and Prognostic Factors in Patients with EGFR Mutant Metastatic Non-Small Cell Lung Cancer Who Treated with Erlotinib

    Clinical Cancer Investigation Journal, 2022

    DOI 10.51847/rvqewyffbi 1 citation (OpenAlex) Open-access full textSource: OpenAlex

  13. Evaluation of Prognostic Factors and Trastuzumab-based Treatments in HER2/Neu-positive Metastatic Gastric Cancer

    Journal of College of Physicians And Surgeons Pakistan, 2022

    DOI 10.29271/jcpsp.2022.08.1014 PMID 35932125 2 citations (Europe PMC) Source: OpenAlex

  14. Effects of Adjuvant Chemotherapy on Insulin Resistance in Patients with Early Breast Cancer

    Cam and Sakura Medical Journal, 2022

    DOI 10.4274/csmedj.galenos.2022.2022-1-7 Source: OpenAlex

  15. Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination.

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.16_suppl.e13031 Source: OpenAlex

  16. The relationship between clinicopathological parameters and PD-L1 expression level in advanced stage non-small cell lung cancer

    Tuberkuloz ve Toraks, 2022

    DOI 10.5578/tt.20229803 PMID 35785877 Source: OpenAlex

  17. Outcomes and prognostic factors in patients with HER2-positive metastatic breast cancer with brain metastasis.

    Journal of Clinical Oncology, 2022

    DOI 10.1200/jco.2022.40.16_suppl.e14002 Source: OpenAlex

  18. Evaluation of clinicopathological features determining treatment response in patients with ALK mutant NSCLC

    Medicine, 2022

    DOI 10.1097/md.0000000000030188 PMID 36042659 Open-access full textSource: OpenAlex

  19. High-dose chemotherapy followed by autologous stem cell transplantation for adult patients With first relapse of Ewing’s sarcoma: A single institution experience

    Medicine, 2022

    DOI 10.1097/md.0000000000032213 PMID 36626465 Open-access full textSource: OpenAlex

  20. Adjuvant Treatment of Gastric Cancer in the D2 Dissection Era: A Real-life Experience from a Multicenter Retrospective Cohort Study

    Euroasian Journal of Hepato-Gastroenterology, 2021

    DOI 10.5005/jp-journals-10018-1343 PMID 34786357 2 citations (Europe PMC) Open-access full textSource: OpenAlex

  21. Real-life comparison of the afatinib and first-generation tyrosine kinase inhibitors in nonsmall cell lung cancer harboring EGFR exon 19 deletion: a Turk Oncology Group (TOG) study

    Journal of Cancer Research and Clinical Oncology, 2021

    DOI 10.1007/s00432-020-03501-6 PMID 33433657 5 citations (Europe PMC) Open-access full textSource: OpenAlex

  22. 1076P Real-world efficacy and safety data of immune checkpoint inhibitors in Turkish patients with metastatic melanoma: A Turkish oncology group study

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.08.1461 Source: OpenAlex

  23. Does nutritional status affect treatment tolerability, chemotherapy response and survival in metastatic gastric cancer patients? Results of a prospective multicenter study in Turkey

    Journal of Oncology Pharmacy Practice, 2021

    DOI 10.1177/1078155220987291 PMID 33435820 12 citations (Europe PMC) Source: OpenAlex

  24. Systemic Immune-Inflammation Index as a Prognostic Marker of Late Recurrence in Operable Gastric Cancer: a Dual-Center Study

    Journal of Gastrointestinal Cancer, 2021

    DOI 10.1007/s12029-021-00769-w PMID 34845631 10 citations (Europe PMC) Source: OpenAlex

  25. Are radiologists ready to evaluate true response to immunotherapy?

    Insights into Imaging, 2021

    DOI 10.1186/s13244-021-00968-w PMID 33625595 7 citations (Europe PMC) Open-access full textSource: OpenAlex

  26. Efficacy and tolerability of vismodegib treatment in locally advanced and metastatic basal cell carcinoma: Retrospective real‐life data

    Dermatologic Therapy, 2021

    DOI 10.1111/dth.15122 PMID 34478210 5 citations (Europe PMC) Source: OpenAlex

  27. Prognostic value of FDG PET-CT in suspected recurrence of colorectal carcinoma: survival outcomes of a 10-year follow-up

    Annals of Nuclear Medicine, 2021

    DOI 10.1007/s12149-021-01684-7 PMID 34648169 2 citations (Europe PMC) Source: OpenAlex

  28. A retrospective multicenter study: Clinicopathological factors affecting recurrence-free survival in operable gastric cancer patients.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.3_suppl.185 Source: OpenAlex

  29. Temozolomide and capecitabine (CAPTEM) is effective in metastatic well-differentiated gastrointestinal neuroendocrine tumors.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.3_suppl.366 Source: OpenAlex

  30. Efficacy of sorafenib in heavily pretreated adult patients with metastatic osteosarcoma.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.15_suppl.e23511 Source: OpenAlex

  31. Efficacy of vincristine, irinotecan, and temozolomide (VIT) combination in adult patients with metastatic Ewing sarcoma.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.15_suppl.e23510 Source: OpenAlex

  32. Abstract PS14-26: Comparison of clinicopathological features in BRCA-wild type and -mutated male breast cancer patients

    Cancer Research, 2021

    DOI 10.1158/1538-7445.sabcs20-ps14-26 Source: OpenAlex

  33. Abstract PS14-25: Outcomes of metastatic male breast cancer

    Cancer Research, 2021

    DOI 10.1158/1538-7445.sabcs20-ps14-25 Source: OpenAlex

  34. Abstract PS10-44: Termination of trastuzumab-based treatment after complete response in HER2-positive metastatic breast cancer

    Cancer Research, 2021

    DOI 10.1158/1538-7445.sabcs20-ps10-44 Source: OpenAlex

  35. Outcomes and prognostic factors in metastatic renal cell carcinoma patients with brain metastases.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.6_suppl.289 Source: OpenAlex

  36. 155P Predictors of treatment response in ALK-positive metastatic non-small cell lung cancer

    Journal of Thoracic Oncology, 2021

    DOI 10.1016/s1556-0864(21)01997-3 Source: OpenAlex

  37. 156P Outcomes of ROS1 positive metastatic lung cancer patients treated with crizotinib

    Journal of Thoracic Oncology, 2021

    DOI 10.1016/s1556-0864(21)01998-5 Source: OpenAlex

  38. Long-term outcomes and predictors of recurrence in patients with early-stage node negative breast cancer.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.15_suppl.e12597 Source: OpenAlex

  39. Predictors of response in EGFR-mutant metastatic non-small cell lung cancer patients treated with tyrosine kinase inhibitors.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.15_suppl.e21149 Source: OpenAlex

  40. Efficacy of sorafenib in symptomatic patients with pretreated progressive desmoid tumors.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.15_suppl.e23556 Source: OpenAlex

  41. Efficacy of temozolomide in pretreated patients with metastatic sarcoma.

    Journal of Clinical Oncology, 2021

    DOI 10.1200/jco.2021.39.15_suppl.e23550 Source: OpenAlex

  42. 772P Hormonal therapy in pretreated patients with metastatic or refractory ovary granulosa cell tumor

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.08.1214 Source: OpenAlex

  43. 19P Predictors of osimertinib response at second-line treatment in EGFR mutant non-small cell lung cancer patients with acquired T790M resistance mutation

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.08.2015 Source: OpenAlex

  44. 16P Evaluation of the relationship between clinicopathological features at diagnosis and acquisition of T790M resistance mutation in patients with EGFR-mutant metastatic lung cancer

    Annals of Oncology, 2021

    DOI 10.1016/j.annonc.2021.08.2012 Source: OpenAlex

  45. PROGNOSTIC AND PREDICTIVE MARKERS OF FOLFIRI/AFLIBERCEPT IN PATIENTS WITH METASTATIC COLORECTAL CANCER (TOG STUDY)

    AYBU AVESIS, 2020

    Source: OpenAlex

  46. Does nutritional status affect treatment tolarability, response and survival in metastatic colorectal cancer patients? Results of a prospective multicenter study

    Journal of Oncology Pharmacy Practice, 2020

    DOI 10.1177/1078155220959427 PMID 32957862 20 citations (Europe PMC) Source: OpenAlex

  47. Does nutritional status affect treatment tolarability, response, and survival in metastatic colorectal cancer patients? Results of prospective multicenter study.

    Journal of Clinical Oncology, 2020

    DOI 10.1200/jco.2020.38.4_suppl.70 Source: OpenAlex

  48. P-357 The frequencies and prognostic significance of ABO blood and rhesus (D) groups in HER2-positive gastric cancer

    Annals of Oncology, 2020

    DOI 10.1016/j.annonc.2020.04.439 Source: OpenAlex

  49. P-355 Trastuzumab-based treatment of HER2-positive metastatic gastric cancer

    Annals of Oncology, 2020

    DOI 10.1016/j.annonc.2020.04.437 Source: OpenAlex

  50. 32P Clinicopathologic features and prognostic factors in male breast cancer: A single centre experience

    Annals of Oncology, 2020

    DOI 10.1016/j.annonc.2020.10.052 Source: OpenAlex